Effect of fiber supplementation on clinical therapeutic response in the experimental group: Delta BASDAI
Clinical response rates observed in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) will be used to measure the percentage of patients responding positively to treatment.
Effect of fiber supplementation on clinical therapeutic response in the experimental group: Delta BASDAI
Clinical response rates observed at 3 months in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) will be used to measure the percentage of patients responding positively to treatment.
Effect of fiber supplementation on clinical therapeutic response in the experimental group: ASAS20
Clinical response rates observed in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
The ASAS20 will be used to measure the percentage of patients responding positively to treatment. This tool was developed by the Assessment of SpondylArthritis international Society (ASAS). The ASAS Response Criteria (ASAS 20) is defined as an improvement in at least 20% and an absolute improvement in at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function, and Inflammation (last 2 questions of BASDAI).
Effect of fiber supplementation on clinical therapeutic response in the experimental group: ASAS20
Clinical response rates observed at 3 months in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
The ASAS20 will be used to measure the percentage of patients responding positively to treatment. This tool was developed by the Assessment of SpondylArthritis international Society (ASAS). The ASAS Response Criteria (ASAS 20) is defined as an improvement in at least 20% and an absolute improvement in at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function, and Inflammation (last 2 questions of BASDAI).
Effect of fiber supplementation on clinical therapeutic response in the experimental group: ASAS40
Clinical response rates observed in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
The ASAS40 will be used to measure the percentage of patients responding positively to treatment. This tool was developed by the Assessment of SpondylArthritis international Society (ASAS). The ASAS Response Criteria (ASAS 40) is defined as an improvement in at least 40% and an absolute improvement in at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function, and Inflammation (last 2 questions of BASDAI).
Effect of fiber supplementation on clinical therapeutic response in the experimental group: ASAS40
Clinical response rates observed at 3 months in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
The ASAS40 will be used to measure the percentage of patients responding positively to treatment. This tool was developed by the Assessment of SpondylArthritis international Society (ASAS). The ASAS Response Criteria (ASAS 40) is defined as an improvement in at least 40% and an absolute improvement in at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function, and Inflammation (last 2 questions of BASDAI).
Effect of fiber supplementation on clinical therapeutic response in the experimental group: ASDAS
Clinical response rates observed at 3 months in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
The ASDAS (Ankylosing Spondylitis Disease Activity Score) will be used to measure the percentage of patients responding positively to treatment. This tool is an index to assess disease activity in Ankylosing Spondylitis. The preferred score uses CRP (C-reactive protein) rather than ESR (erythrocyte sedimentation rate).
Effect of fiber supplementation on clinical therapeutic response in the experimental group: ASDAS
Clinical response rates observed at 3 months in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
The ASDAS (Ankylosing Spondylitis Disease Activity Score) will be used to measure the percentage of patients responding positively to treatment. This tool is an index to assess disease activity in Ankylosing Spondylitis. The preferred score uses CRP (C-reactive protein) rather than ESR (erythrocyte sedimentation rate).
Effect of fiber supplementation on clinical therapeutic response: GIQLI
Clinical response rates in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
Digestive symptoms will be assessed using the Gastrointestinal Quality of Life Index (GIQLI) questionnaire at Week 0 and Week 12. The GIQLI is a measure of the subjective perception of well-being by a patient, which may vary unexpectedly between diagnostic groups. The GIQLI was initiated in Germany and includes 36 items asking about symptoms, physical status, emotions, social dysfunction, and effects of medical treatment. The Questions cover the following 5 dimensions : symptoms, physical condition, emotions, social integration and medical treatment.
Effect of fiber supplmentation on clinical therapeutic response: GIQLI
Clinical response rates observed at 3 months in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
Digestive symptoms will be assessed using the Gastrointestinal Quality of Life Index (GIQLI) questionnaire at Week 0 and Week 12. The GIQLI is a measure of the subjective perception of well-being by a patient, which may vary unexpectedly between diagnostic groups. The GIQLI was initiated in Germany and includes 36 items asking about symptoms, physical status, emotions, social dysfunction, and effects of medical treatment. The Questions cover the following 5 dimensions : symptoms, physical condition, emotions, social integration and medical treatment.
Effect at 12 weeks of placebo on clinical therapeutic response: Delta BASDAI
Clinical response rates observed in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage.
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) will be used to measure the percentage of patients responding positively to treatment.
Effect at 12 weeks of placebo on clinical therapeutic response: Delta BASDAI
Clinical response rates observed at 3 months in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage.
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) will be used to measure the percentage of patients responding positively to treatment.
Effect at 12 weeks of placebo on clinical therapeutic response: ASA20
Clinical response rates observed in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage.
The ASAS20 will be used to measure the percentage of patients responding positively to treatment.This tool was developed by the Assessment of SpondylArthritis international Society (ASAS). The ASAS Response Criteria (ASAS 20) is defined as an improvement in at least 20% and an absolute improvement in at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function, and Inflammation (last 2 questions of BASDAI).
Effect at 12 weeks of placebo on clinical therapeutic response: ASA20
Clinical response rates observed at 3 months in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage.
The ASAS20 will be used to measure the percentage of patients responding positively to treatment.This tool was developed by the Assessment of SpondylArthritis international Society (ASAS). The ASAS Response Criteria (ASAS 20) is defined as an improvement in at least 20% and an absolute improvement in at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function, and Inflammation (last 2 questions of BASDAI).
Effect at 12 weeks of placebo on clinical therapeutic response: ASA40
Clinical response rates observed in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage.
The ASAS40 will be used to measure the percentage of patients responding positively to treatment.This tool was developed by the Assessment of SpondylArthritis international Society (ASAS). The ASAS Response Criteria (ASAS 40) is defined as an improvement in at least 40% and an absolute improvement in at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function, and Inflammation (last 2 questions of BASDAI).
Effect at 12 weeks of placebo on clinical therapeutic response: ASA40
Clinical response rates observed at 3 months in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage.
The ASAS40 will be used to measure the percentage of patients responding positively to treatment.This tool was developed by the Assessment of SpondylArthritis international Society (ASAS). The ASAS Response Criteria (ASAS 40) is defined as an improvement in at least 40% and an absolute improvement in at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function, and Inflammation (last 2 questions of BASDAI).
Effect at 12 weeks of placebo on clinical therapeutic response: ASDAS
Clinical response rates observed at 3 months in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage. The ASDAS (Ankylosing Spondylitis Disease Activity Score) will be used to measure the percentage of patients responding positively to treatment. This tool is an index to assess disease activity in Ankylosing Spondylitis. The preferred score uses CRP (C-reactive protein) rather than ESR (erythrocyte sedimentation rate).
Effect at 12 weeks of placebo on clinical therapeutic response: ASDAS
Clinical response rates observed at 3 months in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage. The ASDAS (Ankylosing Spondylitis Disease Activity Score) will be used to measure the percentage of patients responding positively to treatment. This tool is an index to assess disease activity in Ankylosing Spondylitis. The preferred score uses CRP (C-reactive protein) rather than ESR (erythrocyte sedimentation rate).
Effect of placebo on clinical therapeutic response: GIQLI
Clinical response rates observed in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage.
Digestive symptoms will be assessed using the Gastrointestinal Quality of Life Index (GIQLI) questionnaire at Week 0 and Week 12. The GIQLI is a measure of the subjective perception of well-being by a patient, which may vary unexpectedly between diagnostic groups. The GIQLI was initiated in Germany and includes 36 items asking about symptoms, physical status, emotions, social dysfunction, and effects of medical treatment. The Questions cover the following 5 dimensions : symptoms, physical condition, emotions, social integration and medical treatment.
Effect of placebo on clinical therapeutic response: GIQLI
Clinical response rates observed at 3 months in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage.
Digestive symptoms will be assessed using the Gastrointestinal Quality of Life Index (GIQLI) questionnaire at Week 0 and Week 12. The GIQLI is a measure of the subjective perception of well-being by a patient, which may vary unexpectedly between diagnostic groups. The GIQLI was initiated in Germany and includes 36 items asking about symptoms, physical status, emotions, social dysfunction, and effects of medical treatment. The Questions cover the following 5 dimensions : symptoms, physical condition, emotions, social integration and medical treatment.
Tolerance of anti-IL17 intervention and treatment in the experimental group: Permeability
Changes in serum concentrations of intestinal permeability markers (zonulin, claudin-3, iFABP); and endotoxemia (LBP, CD14s) will be measured by ELISA in ng/ml
Tolerance of anti-IL17 intervention and treatment in controls: Permeability
Changes in serum concentrations of intestinal permeability markers (zonulin, claudin-3, iFABP); and endotoxemia (LBP, CD14s) will be measured by ELISA in ng/ml
Tolerance of anti-IL17 intervention and treatment in the experimental group
The distribution and diversity of different germs will be measured by 16S RNA sequencing.
Quantitative
Tolerance of anti-IL17 intervention and treatment in controls
The distribution and diversity of different germs will be measured by 16S RNA sequencing.
Quantitative
Presence of candida in patients in the experimental group
YES/NO
Presence of candida in patients in the control group
YES/NO
Tolerance of treatment in the experimental group
All adverse events related or not to anti-IL17 treatment and potentially associated with the consumption of high doses of fiber (bloating, flatulence, diarrhea, abdominal pain) will be recorded
Tolerance of treatment in the control group
All adverse events related or not to anti-IL17 treatment and potentially associated with the consumption of high doses of fiber (bloating, flatulence, diarrhea, abdominal pain) will be recorded
Complete blood count: Red blood cells in the experimental group
Red blood cells will be measured in millions/mm3
Complete blood count: Red blood cells in the control group
Red blood cells will be measured in millions/mm3
Complete blood count: Red blood cells in the experimental group
Red blood cells will be measured in millions/mm3
Complete blood count: Red blood cells in the control group
Red blood cells will be measured in millions/mm3
Complete blood count: White blood cells in the experimental group
White blood cells will be measured in millions/mm3
Complete blood count: White blood cells in the control group
White blood cells will be measured in millions/mm3
Complete blood count: White blood cells in the experimental group
White blood cells will be measured in millions/mm3
Complete blood count: White blood cells in the control group
White blood cells will be measured in millions/mm3
Complete blood count: Hemoglobin in the experimental group
Hemoglobin will be measured in g/L
Complete blood count: Hemoglobin in the control group
Hemoglobin will be measured in g/L
Complete blood count: Hemoglobin in the experimental group
Hemoglobin will be measured in g/L
Complete blood count: Hemoglobin in the control group
Hemoglobin will be measured in g/L
Complete blood count: Hematocrit in the experimental group
Hematocrit will be measured as a % of whole blood
Complete blood count: Hematocrit in the control group
Hematocrit will be measured as a % of whole blood
Complete blood count: Hematocrit in the experimental group
Hematocrit will be measured as a % of whole blood
Complete blood count: Hematocrit in the control group
Hematocrit will be measured as a % of whole blood
Complete blood count: Platelets in the experimental group
Platelets will be measured in K/µL
Complete blood count: Platelets in the control group
Platelets will be measured in K/µL
Complete blood count: Platelets in the experimental group
Platelets will be measured in K/µL
Complete blood count: Platelets in the control group
Platelets will be measured in K/µL
T-lymphocytes in the experimental group
The phenotype of T-lymphocytes (Treg, Thelpers) will be measured as % of total white blood cells
T-lymphocytes in the control group
The phenotype of T-lymphocytes (Treg, Thelpers) will be measured as % of total white blood cells
T-lymphocytes in the experimental group
The phenotype of T-lymphocytes (Treg, Thelpers) will be measured as % of total white blood cells
T-lymphocytes in the control group
The phenotype of T-lymphocytes (Treg, Thelpers) will be measured as % of total white blood cells
Monocytes in the experimental group
Monocytes will be measured by flow cytometry (CD25, CD127, CXCR3, CCR6, CD294, CD14, CD16, TNF, IL-6) as % of total white blood cells
Monocytes in the control group
Monocytes will be measured by flow cytometry (CD25, CD127, CXCR3, CCR6, CD294, CD14, CD16, TNF, IL-6) as % of total white blood cells
Monocytes in the experimental group
Monocytes will be measured by flow cytometry (CD25, CD127, CXCR3, CCR6, CD294, CD14, CD16, TNF, IL-6) as % of total white blood cells
Monocytes in the control group
Monocytes will be measured by flow cytometry (CD25, CD127, CXCR3, CCR6, CD294, CD14, CD16, TNF, IL-6) as % of total white blood cells
Aspartate aminotransferase (ASAT) in the experimental group
Aspartate aminotransferase (or ASAT) will be measured in international units per liter
Aspartate aminotransferase (ASAT) in the experimental group
Aspartate aminotransferase (or ASAT) will be measured in international units per liter
Aspartate aminotransferase (ASAT) in the control group
Aspartate aminotransferase (or ASAT) will be measured in international units per liter
Aspartate aminotransferase (ASAT) in the control group
Aspartate aminotransferase (or ASAT) will be measured in international units per liter
Alanine aminotransferase (ALAT) in the experimental group
Alanine aminotransferase (ALAT) will be measured in international units per liter
Alanine aminotransferase (ALAT) in the experimental group
Alanine aminotransferase (ALAT) will be measured in international units per liter
Alanine aminotransferase (ALAT) in the control group
Alanine aminotransferase (ALAT) will be measured in international units per liter
Alanine aminotransferase (ALAT) in the control group
Alanine aminotransferase (ALAT) will be measured in international units per liter
Alkaline phosphatase in the experimental group
Alkaline phosphatase (ALP) will be measured in units per liter
Alkaline phosphatase in the experimental group
Alkaline phosphatase (ALP) will be measured in units per liter
Alkaline phosphatase in the control group
Alkaline phosphatase (ALP) will be measured in units per liter
Alkaline phosphatase in the control group
Alkaline phosphatase (ALP) will be measured in units per liter
Calcium in the experimental group
Calcium will be measured in mmol/L
Calcium in the experimental group
Calcium will be measured in mmol/L
Calcium in the control group
Calcium will be measured in mmol/L
Calcium in the control group
Calcium will be measured in mmol/L
Creatinine in the experimental group
Calcium will be measured in μmol/L
Creatinine in the experimental group
Calcium will be measured in μmol/L
Creatinine in the control group
Calcium will be measured in μmol/L
Creatinine in the control group
Calcium will be measured in μmol/L
Albumin in the experimental group
Albumin will be measured in g/liter
Albumin in the experimental group
Albumin will be measured in g/liter
Albumin in the control group
Albumin will be measured in g/liter
Albumin in the control group
Albumin will be measured in g/liter
Urea in the experimental group
Urea will be measured in mmol/L
Urea in the experimental group
Urea will be measured in mmol/L
Urea in the control group
Urea will be measured in mmol/L
Urea in the control group
Urea will be measured in mmol/L
Bilirubin in the experimental group
Bilirubin will be measured in µmol/L
Bilirubin in the experimental group
Bilirubin will be measured in µmol/L
Bilirubin in the control group
Bilirubin will be measured in µmol/L
Bilirubin in the control group
Bilirubin will be measured in µmol/L
C-Reactive Protein in the experimental group
C-Reactive Protein will be measured in mg/L
C-Reactive Protein in the experimental group
C-Reactive Protein will be measured in mg/L
C-Reactive Protein in the control group
C-Reactive Protein will be measured in mg/L
C-Reactive Protein in the control group
C-Reactive Protein will be measured in mg/L